German biotechnology firm CureVac initiated legal proceedings against Moderna (MRNA.O) on Friday, alleging patent violations concerning COVID-19 vaccine technology, intensifying legal conflicts within the mRNA industry.
This litigation may affect Moderna’s vaccine revenue streams and underscores the growing intellectual property conflicts in the profitable COVID vaccine sector, which generates tens of billions in sales.
Key Takeaways
- CureVac claims Moderna appropriated mRNA stabilization technology for Spikevax vaccine
- BioNTech purchased CureVac last year, initiated separate patent litigation
- Surge of biotech patent conflicts focused on COVID vaccine revenues
Legal Claims and Market Context
CureVac initiated the legal action in Delaware federal court, asserting that Moderna’s COVID-19 vaccine Spikevax violated patents concerning messenger RNA technology 1. The firm pursues royalty payments from Moderna’s Spikevax sales instead of seeking an injunction.
Moderna’s shares have dropped roughly 4% since the lawsuit disclosure. The company had previously initiated legal action against Pfizer and BioNTech in 2022 for patent violations regarding their Comirnaty vaccine, illustrating the interconnected nature of these legal disputes.
Industry Patent War Intensifies
Germany-based BioNTech, which purchased CureVac last year, initiated separate patent litigation against Moderna in February concerning its next-generation mNEXSPIKE COVID-19 vaccine 1. This establishes an intricate network of legal challenges among prominent mRNA vaccine developers.
The litigation forms part of an extensive series of patent lawsuits from biotechnology companies pursuing portions of COVID-19 vaccine profits. Firms such as GlaxoSmithKline, Bayer, and Alnylam Pharmaceuticals have similarly initiated patent actions against vaccine manufacturers.
Technology at the Center of Dispute
CureVac contends that Moderna appropriated its technology for stabilizing delicate mRNA for vaccine applications 1. The legal action encompasses eight U.S. patents covering what CureVac views as fundamental intellectual property for mRNA vaccine platforms.
Moderna stated in a company announcement that it was informed of the litigation and would mount a robust defense. The company has not revealed specific information regarding potential financial liability from the patent allegations.
Historical Context and Future Implications
CureVac was an early mRNA innovator whose proprietary COVID-19 vaccine demonstrated merely 47% effectiveness in advanced trials, causing the company to discontinue that initiative. Despite its commercial setback, CureVac retains substantial patent portfolios in mRNA technology.
The continuing litigation highlights the intricate intellectual property environment surrounding mRNA technology, which has become essential for both COVID-19 vaccines and future therapeutic uses. These legal confrontations may restructure licensing agreements and revenue distribution in the rapidly developing mRNA industry.
Not investment advice. For informational purposes only.
References
1Blake Brittain (April 24, 2026). “CureVac sues Moderna for patent infringement over COVID-19 vaccines”. Reuters. Retrieved April 25, 2026.
2Reuters Legal (April 25, 2026). “German biotech company CureVac sued Moderna in Delaware federal court”. X (formerly Twitter). Retrieved April 25, 2026.
3Jaiveer Shekhawat (April 24, 2026). “CureVac sues Moderna over mRNA vaccine patents”. Investing.com. Retrieved April 25, 2026.
4Guillermo Aquino-Jarquin (November 3, 2022). “The patent dispute over the breakthrough mRNA technology”. Frontiers in Bioengineering and Biotechnology. Retrieved April 25, 2026.
5Blake Brittain (April 24, 2026). “CureVac sues Moderna for patent infringement over COVID-19 vaccines”. TradingView News. Retrieved April 25, 2026.
6Emily J. Thompson (April 24, 2026). “CureVac Sues Moderna Over Patent Infringement”. Intellectia.AI. Retrieved April 25, 2026.
7Jonathan Gardner (July 5, 2022). “CureVac sues rival COVID-19 vaccine maker BioNTech for patent infringement”. BioPharma Dive. Retrieved April 25, 2026.